CHARACTERIZATION OF AMYLIN BINDING-SITES IN A HUMAN HEPATOBLASTOMA CELL-LINE

Amylin binding sites in a human hepatoblastoma cell line (HepG2) have been characterized in detail. I-125-Amylin (rat) bound to HepG2 cells with high affinity. Binding was reversible and selective, and dependent on time and temperature. Scatchard analysis revealed the presence of high (K(d) = 0.11 +/- 0.04 nM) and low (K(d) = 1.3 +/- 0.4 muM affinity binding sites for I-125-amylin in HepG2 cells. The dissociation experiments also showed that I-125-amylin dissociated from high- and low-affinity sites. The association data, however. indicated the presence of only one binding site. Rat amylin was more potent than human amylin and rat calcitonin gene-related peptide (CGRP) in displacing I-125-amylin bound to HepG2 cells. Nonhomologous peptides did not displace I-125-amylin. Rat amylin was, however, less potent than rat CGRP in displacing I-125[Tyr0]CGRP from HepG2 cells. Pretreatment of HepG2 cells with rat amylin (10 nM) reduced the specific binding of I-125-amylin by 75%, whereas rat CGRP (10 nM) pretreatment had no effect on amylin binding. Calcitonin gene-related peptide, as well as rat and human amylin, stimulated the adenylate cyclase activity of HepG2 cell membrane preparation in a dose-dependent manner, with an order of potency of CGRP > rat amylin > human amylin. A CGRP antagonist, CGRP(8-37), significantly attenuated the stimulatory effect of both amylin and CGRP on adenylate cyclase activity. These investigations show that distinct receptors of amylin and CGRP are present in HepG2 cells, and that amylin stimulates adenylate cyclase activity through CGRP receptors. This system could now be exploited for studying amylin receptors and amylin-mediated signal transduction.